Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients
Corresponding Author
O. Hequet
Établissement Français du Sang Auvergne-Rhône-Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Bénite, France
Scientific Department, Établissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France
Laboratory of Allergology and Clinical Immunology, CIRI, Lyon, France
Address reprint requests to: Dr. O. Hequet, MD, PhD, Centre de santé, Etablissement Français du Sang (EFS), Pavillon Marcel Bérard 1G, Centre Hospitalier Lyon Sud. Chemin du Grand Revoyet 69495 Pierre Bénite, France; e-mail: [email protected]Search for more papers by this authorS. Poutrel
Centre de référence constitutif des syndromes drépanocytaires majeurs, des thalassémies et des autres maladies de l'érythropoïèse, Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Search for more papers by this authorP. Connes
Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie vasculaire et du globule rouge", Université Claude Bernard Lyon 1, COMUE Lyon, Villeurbanne, France
Laboratoire d'Excellence sur le globule rouge (Labex GR-Ex), Paris, France
Institut Universitaire de France, Paris, France
Search for more papers by this authorD. Revesz
Établissement Français du Sang Auvergne-Rhône-Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Bénite, France
Search for more papers by this authorY. Chelghoum
Établissement Français du Sang Auvergne-Rhône-Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Bénite, France
Search for more papers by this authorK. Kebaili
Hospices Civils de Lyon, Pediatric Hematology, Institut d'Hematologie et d'Oncologie Pédiatrique, Lyon, France
Search for more papers by this authorG. Cannas
Centre de référence constitutif des syndromes drépanocytaires majeurs, des thalassémies et des autres maladies de l'érythropoïèse, Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Search for more papers by this authorA. Gauthier
Hospices Civils de Lyon, Pediatric Hematology, Institut d'Hematologie et d'Oncologie Pédiatrique, Lyon, France
Search for more papers by this authorA. Guironnet-Paquet
Scientific Department, Établissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France
Laboratory of Allergology and Clinical Immunology, CIRI, Lyon, France
Search for more papers by this authorM. Vocanson
Laboratory of Allergology and Clinical Immunology, CIRI, Lyon, France
Search for more papers by this authorJ.F. Nicolas
Laboratory of Allergology and Clinical Immunology, CIRI, Lyon, France
Search for more papers by this authorC. Renoux
Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie vasculaire et du globule rouge", Université Claude Bernard Lyon 1, COMUE Lyon, Villeurbanne, France
Laboratoire d'Excellence sur le globule rouge (Labex GR-Ex), Paris, France
Laboratoire de Biochimie et Biologie moléculaire Grand Est, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorM. Raba
Etablissement Français du Sang Rhône Alpes, Distribution unit, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Search for more papers by this authorF. Cognasse
Scientific Department, Établissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France
EA3064-GIMAP, Université de Lyon, Saint-Étienne, France
Search for more papers by this authorY. Bertrand
Hospices Civils de Lyon, Pediatric Hematology, Institut d'Hematologie et d'Oncologie Pédiatrique, Lyon, France
Search for more papers by this authorA. Hot
Centre de référence constitutif des syndromes drépanocytaires majeurs, des thalassémies et des autres maladies de l'érythropoïèse, Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Search for more papers by this authorP. Joly
Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie vasculaire et du globule rouge", Université Claude Bernard Lyon 1, COMUE Lyon, Villeurbanne, France
Laboratoire d'Excellence sur le globule rouge (Labex GR-Ex), Paris, France
Laboratoire de Biochimie et Biologie moléculaire Grand Est, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorCorresponding Author
O. Hequet
Établissement Français du Sang Auvergne-Rhône-Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Bénite, France
Scientific Department, Établissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France
Laboratory of Allergology and Clinical Immunology, CIRI, Lyon, France
Address reprint requests to: Dr. O. Hequet, MD, PhD, Centre de santé, Etablissement Français du Sang (EFS), Pavillon Marcel Bérard 1G, Centre Hospitalier Lyon Sud. Chemin du Grand Revoyet 69495 Pierre Bénite, France; e-mail: [email protected]Search for more papers by this authorS. Poutrel
Centre de référence constitutif des syndromes drépanocytaires majeurs, des thalassémies et des autres maladies de l'érythropoïèse, Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Search for more papers by this authorP. Connes
Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie vasculaire et du globule rouge", Université Claude Bernard Lyon 1, COMUE Lyon, Villeurbanne, France
Laboratoire d'Excellence sur le globule rouge (Labex GR-Ex), Paris, France
Institut Universitaire de France, Paris, France
Search for more papers by this authorD. Revesz
Établissement Français du Sang Auvergne-Rhône-Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Bénite, France
Search for more papers by this authorY. Chelghoum
Établissement Français du Sang Auvergne-Rhône-Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Bénite, France
Search for more papers by this authorK. Kebaili
Hospices Civils de Lyon, Pediatric Hematology, Institut d'Hematologie et d'Oncologie Pédiatrique, Lyon, France
Search for more papers by this authorG. Cannas
Centre de référence constitutif des syndromes drépanocytaires majeurs, des thalassémies et des autres maladies de l'érythropoïèse, Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Search for more papers by this authorA. Gauthier
Hospices Civils de Lyon, Pediatric Hematology, Institut d'Hematologie et d'Oncologie Pédiatrique, Lyon, France
Search for more papers by this authorA. Guironnet-Paquet
Scientific Department, Établissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France
Laboratory of Allergology and Clinical Immunology, CIRI, Lyon, France
Search for more papers by this authorM. Vocanson
Laboratory of Allergology and Clinical Immunology, CIRI, Lyon, France
Search for more papers by this authorJ.F. Nicolas
Laboratory of Allergology and Clinical Immunology, CIRI, Lyon, France
Search for more papers by this authorC. Renoux
Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie vasculaire et du globule rouge", Université Claude Bernard Lyon 1, COMUE Lyon, Villeurbanne, France
Laboratoire d'Excellence sur le globule rouge (Labex GR-Ex), Paris, France
Laboratoire de Biochimie et Biologie moléculaire Grand Est, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorM. Raba
Etablissement Français du Sang Rhône Alpes, Distribution unit, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Search for more papers by this authorF. Cognasse
Scientific Department, Établissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France
EA3064-GIMAP, Université de Lyon, Saint-Étienne, France
Search for more papers by this authorY. Bertrand
Hospices Civils de Lyon, Pediatric Hematology, Institut d'Hematologie et d'Oncologie Pédiatrique, Lyon, France
Search for more papers by this authorA. Hot
Centre de référence constitutif des syndromes drépanocytaires majeurs, des thalassémies et des autres maladies de l'érythropoïèse, Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
Search for more papers by this authorP. Joly
Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Equipe "Biologie vasculaire et du globule rouge", Université Claude Bernard Lyon 1, COMUE Lyon, Villeurbanne, France
Laboratoire d'Excellence sur le globule rouge (Labex GR-Ex), Paris, France
Laboratoire de Biochimie et Biologie moléculaire Grand Est, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for more papers by this authorAbstract
BACKGROUND
Chronic red blood cell exchanges (RBCXs) are frequently used to prevent complications in patients with sickle cell anemia, but the scarcity of matched red blood cell packs (RBCPs) is a serious concern. The main goal of this study was to compare the number of RBCPs used during RBCXs between the Spectra Optia (SO) device (with the automatic depletion step) and the former Cobe Spectra (CSP) device.
STUDY DESIGN AND METHODS
The performances and safety of 300 SO sessions using the automatic depletion step (SO/DE) in 50 patients with sickle cell anemia under a chronic transfusion program over a 1-year period were prospectively analyzed. The numbers of RBCPs saved using this protocol compared to the SO device without depletion and to the CSP device were determined.
RESULTS
The SO/DE protocol appeared to be safe, as only 5% and 17% of the sessions were characterized by a significant decrease in blood pressure and increase in heart rate (grade 2 adverse events), respectively. Postapheresis hematocrit and fraction of cells remaining reached expected values. The SO/DE protocol required 16% fewer RBCPs compared to SO without depletion, allowing a mean saving of 12 RBCPs per patient and per year and 13% fewer compared to CSP device. Interestingly, the saving was more important for patients with high total blood volume and/or high preapheresis hematocrit.
CONCLUSION
The SO/DE protocol is an efficient, safe and cost-effective procedure for patients with sickle cell anemia under a chronic transfusion program.
CONFLICT OF INTEREST
The authors have disclosed no conflicts of interest.
REFERENCES
- 1Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010; 376: 2018-31.
- 2Connes P, Renoux C, Romana M, et al. Blood rheological abnormalities in sickle cell anemia. Clin Hemorheol Microcirc 2018; 68: 165-72.
- 3Connes P, Lamarre Y, Waltz X, et al. Haemolysis and abnormal haemorheology in sickle cell anaemia. Br J Haematol 2014; 165: 564-72.
- 4Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc 2018; 68: 263-99.
- 5Ballas SK. Sickle cell disease: classification of clinical complications and approaches to preventive and therapeutic management. Clin Hemorheol Microcirc 2018; 68: 105-28.
- 6Dedeken L, Lê PQ, Rozen L, et al. Automated RBC exchange compared to manual exchange transfusion is cost-effective and reduces iron overload. Transfusion 2018; 58: 1356-62.
- 7Fasano RM, Leong T, Kaushal M, et al. Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients. Transfusion 2016; 56: 1707-15.
- 8Hilliard LM, Williams BF, Lounsbury AE, et al. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 1998; 59: 28-35.
10.1002/(SICI)1096-8652(199809)59:1<28::AID-AJH6>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 9Cabibbo S, Fidone C, Garozzo G, et al. Chronic red blood cell exchange to prevent clinical complications in sickle cell disease. Transfus Apher Sci 2005; 32: 315-21.
- 10Shaz BH, Zimring JC, Demmons DG, et al. Blood donation and blood transfusion: special considerations for African Americans. Transfus Med Rev 2008; 22: 202-14.
- 11Frye V, Caltabiano M, Kesller DA, et al. Evaluating a program to increase blood donation among racial and ethnic minority communities in New York City. Transfusion 2014; 54: 3061-7.
- 12Sarode R, Matevosyan K, Rogers ZR, et al. Advantages of isovolemic hemodilution-red cell exchange therapy to prevent recurrent stroke in sickle cell anemia patients. J Clin Apher 2011; 26: 200-7.
- 13Matevosyan K, Anderson C, Sarode R. Isovolemic hemodilution-red cell exchange for prevention of cerebrovascular accident in sickle cell anemia: the standard operating procedure. J Clin Apher 2012; 27: 88-92.
- 14Perseghin P, Incontri A, Capra M, et al. Erythrocyte-exchange with the OPTIA™ cell separator in patients with sickle-cell disease. J Clin Apher 2013; 28: 411-5.
- 15Perseghin P, Incontri A, Capra M. Erythrocyte-exchange in sickle-cell disease patients. A comparison between Caridian COBE Spectra and Optia cell separators. Transfus Apher Sci 2013; 48: 177.
- 16Kim J, Joseph R, Matevosyan K, et al. Comparison of Spectra Optia and COBE Spectra apheresis systems' performances for red blood cell exchange procedures. Transfus Apher Sci 2016; 55: 368-70.
- 17Quirolo K, Bertolone S, Hassell K, et al. The evaluation of a new apheresis device for automated red blood cell exchange procedures in patients with sickle cell disease. Transfusion 2015; 55: 775-81.
- 18Poullin P, Sanderson F, Bernit E, et al. Comparative evaluation of the depletion-red cell exchange program with the Spectra Optia and the isovolemic hemodilution-red cell exchange method with the Cobe Spectra in sickle cell disease patients. J Clin Apher 2015; 31: 429-33.
- 19 National Cancer Institute, National Institutes of Health U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. NIH publication # 09–7473; Revised Version 4.02 September 15, 2009. [cited 2009 May 29]. Available from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
- 20Sarode R, Ballas SK, Garcia A, et al. Red blood cell exchange; 2015 American Society for Apheresis consensus conference on the management of patients with sickle cell disease. J Clin Apher 2017: 32:342-67.
- 21Billard M, Combet S, Hequet O, et al. Short-term femoral catheter insertion: a promising alternative to consistently allow long-term erythrocytapheresis therapy in children with sickle cell anemia. J Pediatr 2013; 162: 423-6.
- 22Michot JM, Driss F, Guitton C, et al. Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease. Transfusion 2015; 55: 357-63.
- 23Wahl SK, Garcia A, Hagar W, et al. Lower alloimunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. Transfusion 2012; 52: 2671-6.
- 24Corrêa TD, Lima Rocha L, Souza Pessoa CM, et al. Fluid therapy for septic shock resuscitation: which fluid should be used? Einstein (Sao Paulo) 2015; 13: 462-8.
Citing Literature
